INSM

INSMED Inc. 10-Q Summary: Quarter Ended June 30, 2026

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026, for INSMED Inc., a global biopharmaceutical company focused on Respiratory, Immunology & Inflammation, and Neuro & Other Rare therapeutic areas. The company commercializes two primary products: ARIKAYCE (for MAC lung disease) and BRINSUPRI (for non-cystic fibrosis bronchiectasis), which received US approval in August 2025 and European approval in November 2025. As of July 31, 2026, there were 218,381,503 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Net product revenues increased by 296% in Q2 2026 and 265% for the six months ended June 30, 2026, compared to the prior year periods. This growth is primarily driven by the commercial launch of BRINSUPRI in the US ($308.6M in Q2 revenue) and continued international growth of ARIKAYCE.
• Improved Profitability: The net loss narrowed significantly to $13.2 million for Q2 2026 from $321.7 million in Q2 2025. For the six-month period, the loss decreased to $176.8 million from $578.3 million.
• Contingent Consideration Gain: A non-cash gain of $99.8 million (Q2) and $146.7 million (six months) was recorded due to a decrease in the fair value of contingent consideration liabilities, driven largely by a decline in the company's share price and changes in milestone probabilities.
• Expense Growth: SG&A expenses increased by 60% in Q2 and 64% for the six months, primarily due to commercialization activities for BRINSUPRI. R&D expenses increased by 19% in Q2, driven by TPIP clinical development.
• Cost of Revenue Efficiency: Cost of product revenues as a percentage of revenue decreased to 15.8% in Q2 2026 from 26.1% in Q2 2025, attributed to the lower manufacturing costs of BRINSUPRI compared to ARIKAYCE.

Guidance, Outlook, and Risks

• Liquidity: Management states that cash, cash equivalents, and marketable securities ($1.16 billion combined) are sufficient to fund operations for at least the next 12 months. No specific financial guidance for future periods was provided in the text.
• Pipeline Updates:
  • ARIKAYCE: Submitted a US sNDA for newly diagnosed MAC lung disease patients in July 2026; reviewing data with Japan's PMDA for label expansion.
  • BRINSUPRI: Anticipating a regulatory decision in Japan in H2 2026.
  • TPIP: Phase 3 studies (PALM-ILD, PALM-PAH) are enrolling. Positive 12-month data from the Open-Label Extension (OLE) study was reported in July 2026.
  • INS1148: Advancing Phase 2 program for PPF and IPF.
• Risks: Key risks include the ability to successfully commercialize BRINSUPRI, maintain regulatory approvals, obtain reimbursement, and the potential for future capital needs if operating losses persist. The company also faces risks related to third-party manufacturing dependencies and the outcome of ongoing clinical trials.

Investor Verification Checklist

• BRINSUPRI Commercialization: Verify the sustainability of US sales growth and the timeline for international launches (specifically Japan) given the recent approvals.
• Contingent Consideration Volatility: Assess the impact of share price fluctuations on the "Change in fair value of contingent consideration" line item, which significantly reduced reported losses this period.
• Debt Obligations: Review the terms of the $500 million Term Loans (9.6% fixed rate) and the Royalty Financing Agreement (4.0-4.5% of ARIKAYCE sales + 0.75% of BRINSUPRI sales) to understand future cash outflows.
• R&D Burn Rate: Monitor the trajectory of R&D expenses, particularly for TPIP, as Phase 3 trials progress and headcount increases.
• Inventory Levels: Note the increase in inventory to $142.4 million; verify that this aligns with sales velocity to avoid potential write-downs.